

Press Release



Announcement regarding the manufacturing and marketing approval for FREWELL® Combination Tablets LD [ASKA] and ULD [ASKA]

TOKYO, August 15th, 2018 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter "ASKA") has announced that, as of today, ASKA has gained manufacturing and marketing approval regarding FREWELL® Combination Tablets LD [ASKA] and ULD [ASKA] for dysmenorrhea.

FREWELL® Combination Tablets LD [ASKA] and FREWELL® Combination Tablets ULD [ASKA] are the AG (Authorized Generic) medications of LUNABELL® Combination Tablets LD and LUNABELL® Combination Tablets ULD respectively by Nobelpharma Co., Ltd (Head Office: Chuo-ku, Tokyo, President Jin Shiomura:, hereinafter "Nobelpharma").

FREWELL® Combination Tablets LD [ASKA] and ULD [ASKA] is Japan's first low-dose and ultra-low-dose estrogen and progestin combination AG (Authorized Generic) medication.

In November 2016, Nobelpharma and ASKA signed a comprehensive business agreement in the therapeutic area of obstetrics and gynecology, and have been co-promoting products as well as establishing a cooperative relationship.

After the above products are listed within the National Health Insurance drug price list, ASKA will commercialize as well as conduct promotional activities.

The impact of this matter on the business forecast for the fiscal year ending in March 2019, is currently being determined. If any information comes to light that need to be disclosed, it will be done in a timely manner.

[Reference]

Product name	FREWELL® Combination Tablets LD [ASKA]	FREWELL® Combination Tablets ULD [ASKA]
Indication	Dysmenorrhea	
Manufacture and market	ASKA Pharmaceutical Co., Ltd.	
Note	"FREWELL®" is the unified brand name of the generic combination drug of Norethisterone/Ethinylestradiol.	